Surgery for Pulmonary Metastases: Long-Term Survival in 281 Patients
Authors:
- 11 May 2021
- journal article
- research article
- Published by Georg Thieme Verlag KG in The Thoracic and Cardiovascular Surgeon
- Vol. 69 (07) , 660-665
Abstract
Background Despite weak evidence, pulmonary metastasectomy (PM) is widely performed with intent to improve patient survival. Our single-institution analysis aims to evaluate outcomes and to identify factors influencing survival of patients undergoing PM for metastases from wide range of primary tumors. Materials and Methods All patients undergoing curative-intent PM between 2008 and 2018 were retrospectively analyzed. The impact of factors related to primary tumor, metastases, and associated therapy on overall survival (OS) was evaluated using univariable and multivariable Cox proportional hazard models. Cutoff values of continuous variables were determined by a receiver operating characteristic analysis. Results In this study, 281 patients (178 male, median age 61 years) underwent PM. Two (0.7%) perioperative deaths and 23 (8.2%) major complications occurred. Median interval between the treatment of primary tumor and PM was 21 months. Median size of largest metastasis was 1.4 cm. After the median follow-up of 29 months, 134 patients (47.7%) had died. Five-year OS rate after first PM was 47.1%. Complete resection was achieved in 274 (97.5%) patients. Multivariable analysis identified genitourinary origin (hazard ratio [HR]: 0.30, 95% confidence interval [CI]: 0.15–0.60, p = 0.0008) as independent positive survival prognosticator; incomplete resection (HR: 3.53, 95% CI: 1.40–8.91, p = 0.0077) and age at PM of ≥66 years (HR: 1.97, 95% CI: 1.36–2.85, p = 0.0003) were negative prognosticators. Conclusion The use of PM as a part of multimodal treatment is in selected population justified. Our analysis identified age, primary tumor origin, and completeness of resection as independent survival prognosticators. Received: 30 November 2020 Accepted: 13 January 2021 Publication Date: 11 May 2021 (online) © 2021. Thieme. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, GermanyKeywords
This publication has 16 references indexed in Scilit:
- Survival and Prognostic Analysis after Pulmonary Metastasectomy for Head and Neck CancerThe Thoracic and Cardiovascular Surgeon, 2020
- Colorectal cancer: summary of NICE guidanceBMJ, 2020
- Pulmonary metastasectomy for sarcoma—survival and prognostic analysisJournal of Thoracic Disease, 2019
- Value of ablation therapy in the treatment of lung metastasesThoracic Cancer, 2017
- Forty-Two Years' Experience with Pulmonary Resections of Metastases from Colorectal CancerThe Thoracic and Cardiovascular Surgeon, 2016
- Pulmonary Metastasectomy: Common Practice but is it also Best Practice?Future Oncology, 2015
- ACR Appropriateness Criteria® Screening for Pulmonary MetastasesJournal of Thoracic Imaging, 2011
- Oligometastases and Oligo-recurrence: The New Era of Cancer TherapyJapanese Journal of Clinical Oncology, 2010
- Long-term results of lung metastasectomy: Prognostic analyses based on 5206 casesThe Journal of Thoracic and Cardiovascular Surgery, 1997
- Oligometastases.Journal of Clinical Oncology, 1995